Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.

Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.

Deal Snapshot: CEO Stoffels delivered on a recent promise to bring in mid-stage assets, acquiring a firm with a Phase I/IIa CAR-T therapy program for €125m ($131.6m) up front.

Immunology president Patrik Jonsson talked to Scrip about being first to market with a systemic treatment for alopecia areata and launch plans for the new Olumiant indication.

With positive Phase III data for its Xhance (fluticasone propionate) nasal spray in chronic sinusitis, Optinose believes it is poised to expand the target market for the drug 10-fold.

The FDA approved baricitinib for the hair loss disorder despite safety concerns with JAK inhibitors. It carries the same warnings on risk of CV events and malignancy as the others in the class.